A Phase 4 interventional study of Atorvastatin Calcium tablets 80mg and Atorvastatin Calcium tablets 20mg in Acute Ischemic Stroke and Cerebral Microbleeds, sponsored by Sichuan Provincial People's Hospital. Not yet recruiting at 5 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-10-21.
Sponsored by Sichuan Provincial People's Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.
Among the 754 studies in Ischemic Stroke with a site in China, this one is the 241st largest by planned enrollment of the 566 interventional ones that give a count, is one of 92 that started in 2023, is one of 70 in phase 4, reaches primary completion later than 153 of the 399 other live ones, and was the 296th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:
Xidian University · Sites in China
Ages 18+
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Sites in China
Ages 18–85
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
754 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 110 · Phase 3 136 · Phase 4 70
First in 2000; this study’s year is marked. 92 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 344 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 271 across the 566 interventional studies, 625 across the 188 observational. Of the 235 that completed or were terminated, 11 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 754 have an industry lead sponsor. The 10 most frequent:
Sichuan Provincial People's Hospital is the lead sponsor of 78 studies on the registry; 43 are open to participants now.
Sichuan Provincial People's Hospital has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
108 of the studies in Ischemic Stroke with a site in China that are under way reach primary completion within a year, 22 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT) | 2026-11 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06749834Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityIntravenous Thrombolysis and NOAC | 2026-12-31 |
| NCT07335107Phase 3Beijing Tiantan HospitalIntravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion | 2027-01-31 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
Add all 108 to your calendar (.ics) → With an account.
Among the 754 studies in Ischemic Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is the first and largest secondary prevention trial about lipid-lowering therapy for acute ischemic stroke patients at high-risk of intracranial hemorrhage.
The primary hypothesis of this study is: excessive reduction in serum lipid levels by intensive statin therapy in acute ischemic stroke patients with cerebral microbleeds can increase the risk of intracranial hemorrhage.
This study will shed light on new clinical decisions regarding the long-term serum lipid management in these patients with dilemma in clinical practice.
Cerebral microbleeds are an important subtype of cerebral small vessel diseases that have been established in approximately one third of patients with ischemic stroke and are associated with the risk of recurrent ischemic stroke, symptomatic intracranial hemorrhage, and all-cause death. In patients with ischemic stroke or transient ischemic attack, the relative and absolute risks of intracranial hemorrhage increase more rapidly than the risk of ischemic stroke with the increase of cerebral microbleeds burden, but the absolute incidence of ischemic stroke is still higher than that of cerebral hemorrhage.
It has been generally accepted that statins can effectively prevent recurrent ischemic stroke by reducing serum lipid levels. However, both low serum lipid levels and high dose of statins are clear risk factors for intracerebral hemorrhage, and the reduction of major serum lipid levels may increase the risk of cerebral microbleeds. Of note, the risk of statin mediated hemorrhage appears to depend on the degree of lipid reduction rather than statin use per se. These observations raise concerns about the safety of lipid-lowering therapy, especially intensive lipid-lowering therapy, in patients with acute ischemic stroke and cerebral microbleeds who are at high risk for future intracranial hemorrhage. It is still not clear that how to carry on the proper management of serum lipid levels in this particular population to reduce the recurrence of ischemic events as well as hemorrhagic events, for there is still a lack of clinical studies to explore the risk and benefit of different doses of statins to achieve different degrees of lipid regulation.
So, if it is proved that excessive reduction in serum lipid levels by intensive statin therapy in acute ischemic stroke patients with cerebral microbleeds can increase the risk of future intracranial hemorrhage, we will inform new clinical decisions regarding the long-term lipid management in these patients with dilemma in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
atorvastatin calcium tablets 80 mg, quaque nocte, continue to the end of the study
Drug: Atorvastatin Calcium tablets 80mg
atorvastatin calcium tablets 20 mg, quaque nocte, continue to the end of the study
Drug: Atorvastatin Calcium tablets 20mg
Atorvastatin calcium tablets 4 pills (80 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Also known as: ALe produced by Jialin pharmaceutical company
Atorvastatin calcium tablets 1 pill (20 mg) will be given at a fixed time every night (24 ± 1 h between two doses) , orally, until the end of follow-up
Also known as: ALe produced by Jialin pharmaceutical company
The incidence of hemorrhagic strokes
Time frame: From date of randomization until the date of the first occurrence of hemorrhagic stroke, assessed up to 36 months
Changes in degree of cerebral microbleeds
The degree is divided into: mild (1-2), moderate (3-10), severe (more than 10), calculate and compare the proportions of different degrees at baseline and the end of the study
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The Incidence of recurrent ischemic stroke and transient ischemic attack
Time frame: From date of randomization until the date of the first recurrent of ischemic stroke or the first occurrence of transient ischemic attack, assessed up to 36 months
The Incidence of myocardial infarction
Time frame: From date of randomization until the date of the first occurrence of myocardial infarction, assessed up to 36 months
The Incidence of cardiovascular death
Time frame: From date of randomization until the date of cardiovascular death, assessed up to 36 months
The mean of serum triglycerides (TG) levels
Calculate the mean of serum TG levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The mean of serum total cholesterol (TC) levels
Calculate the mean of serum TC levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The mean of serum low-density lipoprotein cholesterol (LDL-C) levels
Calculate the mean of serum LDL-C levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The mean of serum high-density lipoprotein cholesterol (HDL-C) levels
Calculate the mean of serum HDL-C levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The variability of serum triglycerides (TG) levels
Calculate the variability of serum TG levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The variability of serum total cholesterol (TC) levels
Calculate the variability of serum TC levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The variability of serum low-density lipoprotein cholesterol (LDL-C) levels
Calculate the variability of serum LDL-C levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The variability of serum high-density lipoprotein cholesterol (HDL-C) levels
Calculate the variability of serum HDL-C levels for 3 years with at least 3 measurements
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The proportions of different degrees of CMBs at the end of the study
Calculate the proportions of different degrees of CMBs (mild, moderate and severe) at the end of the study
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the mean of serum triglycerides (TG) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the mean of serum total cholesterol (TC) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the mean of serum low-density lipoprotein cholesterol (LDL-C) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the mean of serum high-density lipoprotein cholesterol (HDL-C) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the variability of serum triglycerides (TG) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the variability of serum total cholesterol (TC) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the variability of serum low-density lipoprotein cholesterol (LDL-C) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
The correlation between the variability of serum high-density lipoprotein cholesterol (HDL-C) levels and the proportions of different degrees of CMBs
Time frame: From date of randomization until the end of the study, assessed up to 36 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2023; primary completion for Dec 2026, 47 months later.
Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 47 months is above that.
Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Sichuan Provincial People's Hospital